Breaking News Today – 12th April 2021 AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as an additional […]
Author: Nick
Legal right to 2 week review of patients with suspected heart failure (HF)
The 2010 NICE guidelines recommend that patients with suspected HF should be reviewed by a specialist – within 2 weeks for urgent cases. Patients are presently waiting up to 20 […]
NICE Impact Report Cardiovascular Disease Management
Nice have published their Impact Report on Cardiovascular Disease Management 2021. The Pumping Marvellous Foundation and it’s patients have had an input into this report and provided important insights into […]
NICE Recommends Dapagliflozin for Heart Failure
NICE in the UK recommends Dapagliflozin (FORXIGA) to treat heart failure with reduced ejection fraction for patients with or without Diabetes.
Heart failure and Covid-19 Statement
BSH position statement on the roll out of COVID-19 vaccinations – December 2020 Heart failure and Covid-19 Statement People with heart failure are at increased risk of severe COVID-19. The […]
Heart Failure Marvellous Award Winners 2021 for their outstanding contribution
Heart Failure Doctors, Nurses, NHS Teams, Patients and Carers recognised for marvellous quality of care by the UK’s Heart Failure charity. The Pumping Marvellous Foundation awards are announced for outstanding contribution […]
Alice Fearn and Jai McDowall – Music Will Live in Our Hearts
West End Stars join forces to raise awareness of heart failure Stars’ charity single reassures people with heart failure that there is hope Stars and musicians from the West End […]
World’s First Self-Management Advent Calendar Launches
The Pumping Marvellous Foundation the UK’s Heart Failure Charity launches it’s Christmas Advent Calendar. The World’s First Self-Management Advent Calendar This year we have gone for a unique concept where […]
European commission approves forxiga (dapagliflozin) for heart failure
European commission approves forxiga (dapagliflozin) for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults. PRESS RELEASE Dapagliflozin is the first SGLT2 inhibitor approved in the […]
Impact of COVID-19 and heart failure care in the UK
Findings revealed of first patient survey into the impact of COVID and Heart Failure care in the UK Under 60s report the highest levels of anxiety 65% have reported disruption […]